Description

BSE notifies listing of 6,25,000 new equity shares of EIKO LIFESCIENCES LIMITED (Scrip Code 540204) on preferential basis, effective April 21, 2026, with lock-in until November 2027.

Summary

BSE has notified trading members that 6,25,000 new equity shares of EIKO LIFESCIENCES LIMITED (Scrip Code: 540204) are listed and permitted to trade on the Exchange with effect from Tuesday, April 21, 2026. These shares were issued on a preferential basis to Promoters at Rs. 55/- per share (face value Rs. 10/- with a premium of Rs. 45/-).

Key Points

  • 6,25,000 equity shares of Rs. 10/- each issued at a premium of Rs. 45/- (issue price Rs. 55/-) to Promoters on a preferential basis
  • Shares are ranking pari-passu with existing equity shares of the company
  • Distribution numbers: 13720855 to 14345854
  • ISIN: INE666Q01016
  • Entire allotment of 6,25,000 shares is subject to lock-in until 15/11/2027

Regulatory Changes

No regulatory changes. This is a standard listing notice for newly allotted securities.

Compliance Requirements

Trading members are informed that these securities are now available for trading from April 21, 2026. The lock-in restriction applies to all 6,25,000 shares until November 15, 2027, meaning the Promoter allottees cannot sell or transfer these shares during the lock-in period.

Important Dates

  • Date of Allotment: 24/02/2026
  • Effective Trading Date: Tuesday, April 21, 2026
  • Lock-in Expiry: 15/11/2027

Impact Assessment

This is a routine listing notice with limited broader market impact. The preferential allotment increases the total share count of EIKO LIFESCIENCES LIMITED by 6,25,000 shares. Since all newly listed shares are under lock-in until November 2027, there is no immediate liquidity impact or selling pressure from this allotment. The issuance to Promoters at Rs. 55/- per share reflects the company’s capital-raising activity.

Impact Justification

Routine listing of preferential allotment shares for a small-cap company with no broader market impact; relevant mainly to existing shareholders and the specific scrip.